Urology

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

14th United European Gastroenterology Week

New Insights on Prevention of Colorectal Cancer in Patients with Inflammatory Bowel Disease

Berlin, Germany / October 21-25, 2006

Berlin - There is mounting evidence that 5-aminosalicylic acid (5-ASA) can lower the risk of developing colorectal cancer (CRC) in both Crohn’s disease and ulcerative colitis among patients with inflammatory bowel disease (IBD), yet the...

61st Annual Meeting of the Canadian Urological Association

Preventing Prostate Cancer and Benign Prostatic Hyperplasia Progression

Halifax, Nova Scotia / June 25-28, 2006

Halifax - As discussed here this week, two pivotal trials that examined the effects of using 5-alpha reductase inhibitors in the management of patients with benign prostatic hyperplasia (BPH) are influencing clinical practice. The MTOPS...

61st Annual Meeting of the Canadian Urological Association

Benign Prostatic Hyperplasia: How to Identify Patients at High Risk of Progression

Halifax, Nova Scotia / June 25-28, 2006

Halifax - Benign prostatic hyperplasia (BPH) is a progressive condition that can lead to worsening symptoms, acute urinary retention or surgery. The 5 alpha-reductase (5AR) inhibitors block the conversion of testosterone to...

42nd Annual Meeting of the American Society of Clinical Oncology

Targeted Therapy: A Treatment Advance in Renal Cell Carcinoma

Atlanta, Georgia / June 2-6, 2006

Atlanta - For the past two decades, the treatment of advanced renal cell carcinoma has been limited to two cytokines: interferon alpha (IFNa) and interleukin-2 (IL-2). IFNa is associated with an 11% response rate, while IL-2 has a response...

42nd Annual Meeting of the American Society of Clinical Oncology

Chemopreventive Strategies in Prostate Cancer: Resolving an Enigma

Atlanta, Georgia / June 2-5, 2006

Atlanta - The Prostate Cancer Prevention Trial showed that treatment with the 5-alpha reductase inhibitor finasteride reduced the period prevalence of prostate cancer by 25% over its seven-year span compared with placebo. However, questions...

101st Annual Meeting of the American Urological Association (AUA)

Novel Findings and Therapy Strategies in Prostate Disease

Atlanta, Georgia / May 20-25, 2006

Atlanta - With the aging of western populations, the spectre of prostate disease emerges as a major health issue, with an estimated 12 million men in the US who have enlarged prostates and another 1.6 million who have prostate cancer. The...

101st Annual Meeting of the American Urological Association

The Evolution of 5-alpha Reductase Inhibition in Benign Prostatic Hyperplasia and Prostate Cancer Prevention

Atlanta, Georgia / May 20-25, 2006

Atlanta - Prostate disease poses a major health issue whose scope and consequences will continue to grow as Western populations age. According to the National Cancer Institute of Canada, in 2006, almost 21,000 Canadian men will be diagnosed...

21st Annual Congress of the European Association of Urology

Finding the Key to Dihydrotestosterone Control in Prostate Cancer Prevention

Paris, France / April 5-8, 2006

Paris - Dihydrotestosterone (DHT) plays a central role in both normal and abnormal prostate growth. Manipulation of DHT levels via inhibition of the enzyme 5 alpha-reductase (5AR) has proven to be an effective means of treating benign...

21st Annual Congress of the European Association of Urology

Multikinase Inhibition in the Management of Renal Cell Carcinoma: The Role of Urologists

Paris, France / April 5-8, 2006

Paris - Greater understanding of molecular biology and the impact of genetic mutations on intracellular pathways in kidney cancer cells has led to the identification of several receptors and signalling molecules as targets for the treatment...

21st Annual Congress of the European Association of Urology

Overactive Bladder: Examining New Therapeutic Avenues

Paris, France / April 5-8, 2006

Paris - According to the World Health Organization, bladder control problems affect more than 200 million people worldwide, with overactive bladder (OAB) being one of the most common and troublesome causes. OAB symptoms can be bothersome,...

PAGE 7 OF 8   1 2 3 4 5 6 7 8